As of Jul 22
| +0.01 / +0.46%|
The 6 analysts offering 12-month price forecasts for Conatus Pharmaceuticals Inc have a median target of 6.50, with a high estimate of 17.00 and a low estimate of 4.00. The median estimate represents a +195.45% increase from the last price of 2.20.
The current consensus among 6 polled investment analysts is to Buy stock in Conatus Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.